Terri A. Sewell

11/19/2026 | Press release | Distributed by Public on 11/19/2026 16:37

Rep. Sewell Hosts World Pancreatic Cancer Day Roundtable Highlighting Landmark Advances in Detection and Treatment

Washington, D.C. - Today, U.S. Rep. Terri Sewell (AL-07) convened lawmakers, researchers, advocates, industry experts, and a pancreatic cancer survivor for a roundtable discussion on Capitol Hill marking World Pancreatic Cancer Day and highlighting groundbreaking advances in pancreatic cancer detection and treatment. The discussion focused on the historic progress made in 2026, the importance of sustained federal investment in cancer research, and the work still needed to improve outcomes for patients and families.

Additional photos are available here.

"2026 has shown us what is possible when we invest in groundbreaking research, embrace medical innovation, and work together to put patients first," said Rep. Sewell. "From the FDA's approval of a promising new targeted treatment to the enactment of our Nancy Gardner Sewell MCED Act, we are making meaningful progress in the fight against cancer. But we cannot afford to let up now. I will continue fighting to increase federal investments in pancreatic cancer research and ensure that patients and families have access to the breakthroughs that can save lives. Our goal must be to make early detection more accessible, expand treatment options, and turn today's progress into tomorrow's cures."

The roundtable featured Julie Fleshman, JD, MBA, President and CEO of the Pancreatic Cancer Action Network (PanCAN); Brian Wolpin, MD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School; Don Frost, PharmD, MBA, Senior Director of Payer and Health Systems Liaison at Revolution Medicines; and Joe Damore, a pancreatic cancer survivor.

This year has marked a landmark moment in the fight against pancreatic cancer. In August, the Food and Drug Administration (FDA) approved RASONQUE (daraxonrasib), the first broad RAS-targeted treatment for metastatic pancreatic cancer. The groundbreaking therapy represents a major step forward for patients with advanced disease, offering a new treatment option against a cancer that has historically been extremely difficult to treat.

The year also brought a historic victory for early cancer detection with the enactment of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, bipartisan legislation led by Rep. Sewell and signed into law in February. The law establishes a pathway for Medicare coverage of qualifying multi-cancer early detection tests once FDA approved, helping ensure that seniors can benefit from emerging technologies capable of detecting multiple cancers through a single screening test.

"On World Pancreatic Cancer Day, we celebrate an extraordinary year of progress for pancreatic cancer patients with breakthroughs in research that were once thought impossible, but we know more work is needed," said Julie Fleshman, JD, MBA, President and CEO of PanCAN. "Thanks to the leadership of Representative Sewell and the continued federal investment in pancreatic cancer research, advances are bringing new hope to patients and families. We must build on this momentum by continuing to increase the federal investment in cancer research to ensure the next generation of breakthroughs reaches patients who need them and survival becomes the expectation, not the exception."

Rep. Sewell has also made increasing federal investment in pancreatic cancer research a priority. Earlier this year, she successfully led the effort to restore and increase appropriations for pancreatic cancer research through in the Congressionally Directed Medical Research Program (CDMRP) in the FY26 defense bill after funding for the program was completely eliminated in FY25 under Republicans' continuing resolution. Sewell secured a historic $20 million for the program, a $5 million increase from FY24 funding levels. Building on that achievement, she secured an additional $25 million in the House-passed FY2027 defense appropriations bill.

Pancreatic cancer remains among the deadliest forms of cancer, in large part because it is often diagnosed at an advanced stage when treatment options are limited. Today's roundtable underscored the importance of continued collaboration among researchers, medical professionals, advocates, industry leaders, policymakers, and survivors to accelerate scientific discovery and ensure that promising advances reach the patients who need them most.

###

Terri A. Sewell published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 22:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]